NEW APPROACH: Drugmaker Merck & Co. has retooled research operations to get more bang for the buck, while it's boosting sales of existing drugs, pushing harder into key markets and continuing to rein in spending.
DIVDEND BOOST: For the first time since pulling painkiller Vioxx off the …
Комментариев нет:
Отправить комментарий